A study led by Prof. Liang Xingjie's team from the National Center for Nanoscience and Technology of the Chinese Academy of ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...

Anixa Biosciences' breast cancer vaccine elicited targeted immune responses in 70% of patients. Click here to read an ...

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA ...

I’ve endured numerous rounds of radiation and taken thousands of pills—but CAR-T is the most effective therapy I’ve completed ...

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced the issuance of a new standard patent by the Hong Kong ...

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.